Online Program Home
My Program

Abstract Details

Activity Number: 306
Type: Contributed
Date/Time: Tuesday, August 2, 2016 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #321111 View Presentation
Title: Use of the Treatment-Free Interval in Driving Decision Making in Cancer Care: A Late-Phase Example
Author(s): Suddhasatta Acharyya* and Ashok Panneerselvam and Sofia Paul
Companies: Novartis and Novartis Oncology and Novartis
Keywords: progression-free-survival ; treatment-free-interval ; oncology ; risk-benefit
Abstract:

Healthcare providers and drug makers now have to deliver a compelling value proposition in oncology to stay relevant in an increasingly crowded market with multiple therapeutic options. This means a significant improvement in the risk-benefit ratio will become an even more critical decision driver in cancer care. In this context, a metric that looks at the 'net benefit' rather than the absolute benefit is very appealing to both patients and payers. One such metric is the 'treatment-free-interval (TFI)' which is generally defined as the time from discontinuation of treatment to the start of disease progression. Our computation of TFI is based on partitioned survival analysis and makes use of the mean time to events of interest. The application of this methodology to specific clinical trials often brings up analytical issues, some of which will be discussed, as they apply to a large phase 3 oncology study.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association